Sentences with phrase «in pharmaceutical stock»

Not exact matches

In 2015, Ackman, the founder of hedge fund Pershing Square, announced his multi-billion dollar bet on Valeant Pharmaceuticals (vrx); he proceeded to lose nearly his entire investment, or $ 7.7 million every day for about two years, as Valeant stock sank 95 %.

After witnessing a 95 % decline in the pharmaceutical company's share price amid a series of scandals, Valeant's board, led by former shareholder and hedge fund manager Bill Ackman, smartly tied Papa's compensation to a recovery in the stock price.

BOSTON, April 20 (Reuters)- Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $ 25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene - silencing technology used to develop drug treatments.

While exorbitant drug price hikes by Martin Shkreli's Turing Pharmaceuticals and Valeant have sparked outrage in Washington and tanked the stock prices of much of the pharmaceutical sector in the last six months, there's growing evidence that the controversy may be more smoke than fire.

Teva Pharmaceuticals has proposed buying rival Mylan for $ 40 billion in cash and stock, as the Israel - based drugmaker looks to gain dominance among generic pharmaceutical companies.

Editor's note: An earlier version of this story said Teva Pharmaceuticals has proposed buying rival Mylan for $ 40 million in cash and stock.

Generic drugmaker Mylan has proposed buying Perrigo for about $ 29 billion in cash and stock in what would be the biggest pharmaceutical deal of the year so far.

One of those stocks is Actavis, the large - cap pharmaceutical company that has tripled in returns over the last three years.

Pharma and biotech stocks swooned recently (the S&P Pharmaceuticals Select Industry Index is down 25 % in the last three months), largely on concerns about greater drug price regulation.

PTCT, +3.33 % plans to buy privately - held Marathon Pharmaceuticals» controversial Duchenne muscular dystrophy drug for about $ 75 million in cash and $ 65 million in PTC common stock.

All told, we continue to view Merck & Co. stock as a solid core holding for investors seeking participation in the large pharmaceutical space.

In terms of valuation, Valeant Pharmaceuticals stock currently trades at TTM price to sales value of 0.58 x and price to book value of 1.40 x.

Represented a pharmaceutical company in its Series B and Series C Preferred Stock financing in which $ 5M and $ 30M, respectively, was raised.

In May generic drug company Actavis Inc. agreed to buy Warner Chilcott PLC for $ 8.5 billion in stock, creating the third - biggest specialty pharmaceutical company in the U.S. markeIn May generic drug company Actavis Inc. agreed to buy Warner Chilcott PLC for $ 8.5 billion in stock, creating the third - biggest specialty pharmaceutical company in the U.S. markein stock, creating the third - biggest specialty pharmaceutical company in the U.S. markein the U.S. market.

NEW YORK (TheStreet)-- With Shire (SHPG) offering to acquire Baxalta (BXLT) for more than $ 30 billion, we decided to check TheStreet Quant Ratings for stocks in the pharmaceuticals subsector that would be good investments.

Adamas Pharmaceuticals Inc (NASDAQ: ADMS), a small - cap pharmaceutical company that develops therapies to treat chronic neurologic disorders, is a «misunderstood» stock that has a potential upside of four times, Kerrisdale Capital said in a new report.

The last major takeover that Pfizer completed was the buyout of Wyeth Pharmaceuticals in 2009 for $ 68 billion in cash and stock.

We recently bought Alexion Pharmaceuticals ($ ALXN) in our Wagner Daily ETF and stock newsletter, and this post is an educational walk - through of the technical setup and subsequent trade management.

Yulia has a diverse experience of managing legal teams and projects in investments, telecommunication, metal production and pharmaceuticals, including corporations listed on NASDAQ, Hong Kong Stock exchange and Moscow Stock exchange.

Sally Evans, a 61 - year - old pharmaceutical - industry sales analyst in the Chicago area, recalls her friends «bailing from the market,» even as she increased her retirement - account contributions and invested more aggressively in stocks.

Caribou (CBOU), GT Solar (SOLR), which was featured in my June 3rd update, EasyLink Services (ESIC), Pharmacyclics (PCYC) and SciClone Pharmaceuticals (SCLN), featured in the May 17th list, are all repeat stocks appearing on this week's list.

Now, in the IMS Health case, a big part of explaining why investors might take such a deal is that it offered a nice premium over the recent stock price and they might have been comparing IMS Health to pharmaceutical companies (IMS Health's customers) instead of pharmaceutical services companies (IMS Health's peers).

Recently, we did so with a swing trade in Onyx Pharmaceuticals ($ ONXX), which enabled us to score a 10 % gain on the price of the stock over just a 3 - day holding period.

However, if there's a company with Nike - like return potential in the works, I believe it to be budding biotech stock Ligand Pharmaceuticals.

With almost 200 stocks in its portfolio, the iShares ETF claims about 80 % of its assets are invested in biotechnology specifically, with the remaining 20 % split between pharmaceutical companies and businesses specializing in tools and services for the life sciences industry.

Sean Williams (Ionis Pharmaceuticals): If you've been gazing in wonder at the delectable returns that biotech stocks can generate for your portfolio, but you've yet to take the plunge, may I suggest dipping your toes in the water with Ionis Pharmaceuticals?

No. 3: The year of big pharma In the past five years, big cap pharmaceutical stocks have lagged biotech stocks because they've struggled to fill revenue gaps created by the patent cliff.

The Catholic MP linked to an Indonesian firm which manufacturer a pill which causes terminations, has dumped stock he held in a different pharmaceutical firm in India, which also sells abortion drugs.

Any newcomer will have to come to terms not only with the most dismal NCI budget scenario in 3 decades but also with stringent new rules on owning pharmaceutical stock; and because this is a presidential appointment, the director might have less than 2 years to serve.

It could have a dramatic impact on productivity, which in turn could have a major impact on the valuation of pharmaceutical stocks,» he said.

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the outcome of the review of the continued listing of our common stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

I thought about investing in stocks in the pharmaceutical industry, because people might get ill and stressed out more often.

For example, I'm considering buying funds invested in the Biotech, Software / IT, Retailing, Pharmaceuticals, and Chemicals sectors of the market, which have outperformed the typical 7 % average annual return of a typical «all stocks all sectors» portfolio.

Consolidation and high volume are necessary to generate sufficient profits to justify higher stock valuations given the extremely competitive and sometimes deflationary environment in the pharmaceutical retailers industry.

The U.S. market in particular offers a wealth of sectors that are minimal or non-existent in Canada: high - tech, pharmaceuticals and bio-tech, defence stocks, social media stocks and many more.

Edited by analyst Nancy Zambell, this service has helped readers gain profits that have been simply breathtaking: +1,683 % in Questcor from Richard Schmidt's Stellar Stocks Alert, +857 % in Baidu from Charles B. Carlson, CFA, Drip Investor, +728 % in Valeant Pharmaceuticals from Ronald Sadoff's Major Trends, + 545 % in SanDisk from George Putnam, III, The Turnaround Letter, +389 % in Headwaters from Nick Hodge, Alternative Energy Speculator and 367 % in Core Labs from Joseph Parnes, Shortex Market Letter.

These are the funds / schemes which invest in the securities of only those sectors or industries as specified in the offer documents, e.g., Pharmaceuticals, Software, Fast Moving Consumer Goods (FMCG), Petroleum stocks, Information Technology (IT), Banks, etc..

Back when the Canadian dollar was trading roughly at par with the U.S. dollar (and briefly above it), it was a great opportunity for Canadian investors to diversify outside of the Canadian equity market to buy world - class U.S. stocks in sectors underrepresented in Canada: technology, health care, pharmaceuticals, consumer staples and the like.

Stock investments can range from stable, blue - chip companies to speculative issues in pharmaceuticals, technology, mining or other sectors.

The Slater Zulu Principle Screen throws up stocks such as Solid State, which manufactures specialist electronic components, Telford Homes and Telit Communications while the Buffettology-esque Historical Growth Screen points to stocks such as Avon Rubber, the engineering company, Shire, the pharmaceutical business and Magnit PAO, which operates convenience stores and hypermarkets in the Russian Federation.

Posted in About, Autobytel (NASDAQ: ABTL), Avigen (NASDAQ: AVGN), Axcelis Technologies Inc (NASDAQ: ACLS), Ditech Networks Inc (NASDAQ: DITC), Greenbackd, Greenbackd Portfolio, Liquidation Value, MathStar Inc (OTC: MATH), Network Engines Inc (NASDAQ: NENG), Neurobiological Technologies Inc (NASDAQ: NTII), Northstar Neuroscience Inc (NASDAQ: NSTR), Rackable Systems Inc (NASDAQ: RACK), Soapstone Networks Inc (NASDAQ: SOAP), Stocks, Vanda Pharmaceuticals Inc (NASDAQ: VNDA), VaxGen Inc (OTC: VXGN) Tagged Activist investment, Autobytel Inc (NASDAQ: ABTL), Avigen Inc (NASDAQ: AVGN), Axcelis Technologies Inc (NASDAQ: ACLS), Ditech Networks Inc (NASDAQ: DITC), MathStar Inc (OTC: MATH), Northstar Neuroscience Inc (NASDAQ: NSTR), Soapstone Networks Inc (NASDAQ: SOAP) Leave a Comment

While the SEC and the IRS are not completely clear on what a «substantially similar stock» means exactly, to be on the safe side, it is important that if stock A was a stock in the pharmaceutical industry, you don't purchase an identical stock from an identical pharmaceutical company (stock B) within that 30 - day window.

Posted in Activist Investors, Net Cash Stocks, Stocks, Tang Capital Partners, Vanda Pharmaceuticals Inc (NASDAQ: VNDA) Tagged Activist investment, Liquidating Value, Net Cash Stock, Tang Capital Partners, Vanda Pharmaceuticals Inc (NASDAQ: VNDA) 4 Comments

This sounded great, but no stocks actually trade that cheaply anymore — other than, say, a Chinese pharmaceutical company accused of accounting fraud, or a shell company run out of a garage in Toledo.

Posted in Activist Investors, Net Cash Stocks, Stocks, Tang Capital Partners, Vanda Pharmaceuticals Inc (NASDAQ: VNDA) Tagged Activist investment, Liquidating Value, Net Cash Stock, Tang Capital Partners, Vanda Pharmaceuticals Inc (NASDAQ: VNDA) Leave a Comment

Often, realtors own rental real estate, Silicon Valley employees dabble in technology stocks and doctors buy shares in pharmaceutical companies.

The Agios Pharmaceuticals, Inc. (AGIO) mid-term technical analysis below is based on the analysis of the recent price trend of the AGIO stock, changes in trading volume and money flow.

Posted in Activist Investors, Net Cash Stocks, Stocks, Tang Capital Partners, Vanda Pharmaceuticals Inc (NASDAQ: VNDA), tagged Activist investment, Liquidating Value, Net Cash Stock, Tang Capital Partners, Vanda Pharmaceuticals Inc (NASDAQ: VNDA) on March 12, 2009 4 Comments»

Posted in Activist Investors, Net Cash Stocks, Stocks, Tang Capital Partners, Vanda Pharmaceuticals Inc (NASDAQ: VNDA), tagged Activist investment, Net Cash Stock, Tang Capital Partners, Vanda Pharmaceuticals Inc (NASDAQ: VNDA) on April 30, 2009 5 Comments»

Posted in About, Activist Investors, Carl Icahn, Poison Pills, Stocks, tagged Activist investment, Amylin Pharmaceuticals Inc. (NASDAQ: AMLN), Carl Icahn on April 22, 2009 Leave a Comment»